OncoMatch/Clinical Trials/NCT06783790
Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT
Is NCT06783790 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Avapritinib, azacitidine, Venetoclax for aml (acute myelogenous leukemia).
Treatment: Avapritinib, azacitidine, Venetoclax — This is a single-center, prospective, single-arm, exploratory clinical study. To explore the efficacy and safety of avapritinib in patients with recurrent acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation with C-KIT mutation RUNX1::RUNX1T1 or CBFB::MYH11.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: KIT D816 mutation
Bone marrow molecular biology detected C-KIT D816 or C-KIT N822 mutations
Required: KIT N822 mutation
Bone marrow molecular biology detected C-KIT D816 or C-KIT N822 mutations
Required: CBFB CBFB::MYH11 fusion gene
Patients with CBFB::MYH11 gene detected
Required: RUNX1 RUNX1::RUNX1T1 fusion gene
Patients with RUNX1::RUNX1T1 fusion gene detected
Excluded: FLT3 ITD mutation
FLT3-ITD mutation in patients with recurrent/refractory disease (except low gene ratio)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: allogeneic stem cell transplant
recurrence after allogeneic transplantation
Cannot have received: KIT inhibitor (Midostaurin)
Patients who have received previous treatment with Midostaurin
Cannot have received: mutation-specific KIT inhibitor
Exception: except if no disease progression during treatment
Patients who have previously been treated with mutation-specific C-KIT inhibitors and have developed disease progression during treatment
Lab requirements
Kidney function
creatinine ≤1.5 upper limit of normal value
Liver function
Total bilirubin ≤2×ULN; ALT and AST≤2.5 x ULN; Myocardial enzymes < 2 times the upper limit of normal (for the same age)
Cardiac function
Left ventricular ejection fraction ≥50%; Blood oxygen saturation >91%
Liver, kidney and cardiopulmonary functions met the following requirements: Within 2 weeks before enrollment ① creatinine ≤1.5 upper limit of normal value; ② Left ventricular ejection fraction ≥50%; ③ Blood oxygen saturation >91%; ④ Total bilirubin ≤2×ULN; ALT and AST≤2.5 x ULN; Myocardial enzymes < 2 times the upper limit of normal (for the same age)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06783790 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior KIT inhibitor, mutation-specific KIT inhibitor disqualifies patients from enrollment.
Does this trial require KIT?
Yes, KIT D816 mutation is a required biomarker for enrollment.
Does this trial require KIT?
Yes, KIT N822 mutation is a required biomarker for enrollment.
Does this trial require CBFB?
Yes, CBFB CBFB::MYH11 fusion gene is a required biomarker for enrollment.
Are patients with FLT3 alterations eligible?
No. FLT3 ITD mutation is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages